{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:09Z","timestamp":1786998309242,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004064","name":"Prostate Cancer Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102910","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:32:10Z","timestamp":1783006330000},"page":"102910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Samuel J.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minae","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graydon","family":"Moorhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Haradhvala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102910_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102910_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102910_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2026.102910_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","volume":"31","author":"Shitara","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102910_bib5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","article-title":"Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer","volume":"11","author":"Kwon","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102910_bib6","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1038\/s41467-022-32627-z","article-title":"scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory","volume":"13","author":"Sun","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102910_bib7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/2159-8290.CD-23-0857","article-title":"Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer","volume":"14","author":"An","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102910_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ccell.2023.04.012","article-title":"RECISTv1.1 progression in oncology: Shades of gray","volume":"41","author":"Topp","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102910_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gutjnl-2023-330748","article-title":"Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy","volume":"73","author":"O\u2019Rourke","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.102910_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102910_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102910_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41587-023-01940-3","article-title":"Supervised discovery of interpretable gene programs from single-cell data","volume":"42","author":"Kunes","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102910_bib13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.ccell.2024.09.011","article-title":"A pan-cancer single-cell RNA-seq atlas of intratumoral B cells","volume":"42","author":"Fitzsimons","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102910_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102910_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102910_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102910_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102910_bib18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102910_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102910_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102910_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102910_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102910_bib23","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102910_bib24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102910_bib25","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","article-title":"Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab","volume":"30","author":"Alban","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102910_bib26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor Epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102910_bib27","unstructured":"Gayoso, A., and Shor, J. (2025). JonathanShor\/DoubletDetection: doubletdetection v4.3.0.post1. Zenodo."},{"key":"10.1016\/j.xcrm.2026.102910_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102910_bib29","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T cell states from single-cell transcriptomics data using reference atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102910_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102910_bib31","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41596-019-0195-x","article-title":"RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis","volume":"14","author":"Li","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102910_bib32","doi-asserted-by":"crossref","first-page":"D468","DOI":"10.1093\/nar\/gkaa796","article-title":"TCRdb: a comprehensive database for T-cell receptor sequences with powerful search function","volume":"49","author":"Chen","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102910_bib33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102910_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102910_bib35","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","article-title":"UCell: Robust and scalable single-cell gene signature scoring","volume":"19","author":"Andreatta","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:03:14Z","timestamp":1784646194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126003277"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102910","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102910"}}